Cargando…

Lack of tolerable treatment options for patients with schizophrenia

PURPOSE: Atypical antipsychotics (AAs), an effective treatment for schizophrenia, have a range of pharmacologic properties leading to differences in tolerability as well as heterogeneity in treatment response. Individual patient characteristics must be considered when making treatment choices, espec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Citrome, Leslie, Eramo, Anna, Francois, Clement, Duffy, Ruth, Legacy, Susan N, Offord, Steve J, Krasa, Holly B, Johnston, Stephen S, Guiraud-Diawara, Alice, Kamat, Siddhesh A, Rohman, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689285/ https://www.ncbi.nlm.nih.gov/pubmed/26719694 http://dx.doi.org/10.2147/NDT.S91917

Ejemplares similares

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
por: Aigbogun, Myrlene S, et al.
Publicado: (2018)

The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review
por: Maletic, Vladimir, et al.
Publicado: (2017)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
por: Karson, Craig, et al.
Publicado: (2016)

A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting
por: François, Clément, et al.
Publicado: (2017)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome, Leslie
Publicado: (2018)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
por: Citrome, Leslie
Publicado: (2013)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward, Kristen, et al.
Publicado: (2019)

Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
por: Zeller, Scott L., et al.
Publicado: (2016)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
por: Sapin, Christophe, et al.
Publicado: (2016)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden, Justin, et al.
Publicado: (2019)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

Correction to: Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
por: Citrome, Leslie, et al.
Publicado: (2022)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
por: Citrome, Leslie, et al.
Publicado: (2022)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study
por: Citrome, Leslie, et al.
Publicado: (2022)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman, Phyllis M, et al.
Publicado: (2017)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Citability of Original Research and Reviews in Journals and Their Sponsored Supplements
por: Citrome, Leslie
Publicado: (2010)

Do People with Schizophrenia Lack Emotional Intelligence?
por: Dawson, Sara, et al.
Publicado: (2012)

Optimizing dosing in atypical neuroleptic monotherapy
por: Trémeau, Fabien, et al.
Publicado: (2002)

Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
por: Faden, Justin, et al.
Publicado: (2020)

The loss of enzymatic activity of the PHARC‐associated lipase ABHD12 results in increased phagocytosis that causes neuroinflammation
por: Singh, Shubham, et al.
Publicado: (2021)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
por: Citrome, Leslie, et al.
Publicado: (2021)

Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia
por: Stummer, Lauren, et al.
Publicado: (2018)

Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
por: Greenberg, William M., et al.
Publicado: (2015)

Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management
por: Ward, Kristen M., et al.
Publicado: (2018)

Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Implications of the lack of desiccation tolerance in recalcitrant seeds
por: Berjak, Patricia, et al.
Publicado: (2013)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2qmlo42nbl6me0d1t4sk9tbr84